| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Endothelial Growth Factors | 40 | 2003 | 694 | 3.870 |
Why?
|
| Lymphokines | 39 | 2003 | 949 | 3.670 |
Why?
|
| Diabetic Retinopathy | 34 | 2022 | 1210 | 3.600 |
Why?
|
| Vascular Endothelial Growth Factor A | 72 | 2022 | 3508 | 3.040 |
Why?
|
| Aptamers, Nucleotide | 15 | 2009 | 166 | 2.040 |
Why?
|
| Macular Degeneration | 18 | 2022 | 980 | 2.030 |
Why?
|
| Angiogenesis Inhibitors | 20 | 2022 | 2038 | 1.710 |
Why?
|
| Macular Edema | 9 | 2022 | 359 | 1.660 |
Why?
|
| Retinal Vessels | 23 | 2014 | 772 | 1.630 |
Why?
|
| Choroidal Neovascularization | 17 | 2021 | 343 | 1.620 |
Why?
|
| Neovascularization, Pathologic | 22 | 2016 | 2635 | 1.610 |
Why?
|
| Blood-Retinal Barrier | 13 | 2007 | 62 | 1.560 |
Why?
|
| Intercellular Adhesion Molecule-1 | 18 | 2007 | 1155 | 1.350 |
Why?
|
| Vascular Endothelial Growth Factors | 39 | 2003 | 772 | 1.230 |
Why?
|
| Retina | 27 | 2009 | 2616 | 1.220 |
Why?
|
| Corneal Neovascularization | 11 | 2008 | 188 | 1.170 |
Why?
|
| Wet Macular Degeneration | 2 | 2022 | 145 | 0.880 |
Why?
|
| Eye | 7 | 2015 | 729 | 0.830 |
Why?
|
| Leukostasis | 5 | 2007 | 22 | 0.810 |
Why?
|
| Retinal Neovascularization | 6 | 2005 | 244 | 0.800 |
Why?
|
| Vitreous Body | 19 | 2024 | 389 | 0.800 |
Why?
|
| Cornea | 15 | 2008 | 1524 | 0.760 |
Why?
|
| Endothelium, Vascular | 20 | 2006 | 4456 | 0.760 |
Why?
|
| Diabetes Mellitus, Experimental | 10 | 2007 | 1116 | 0.730 |
Why?
|
| Choroid | 9 | 2014 | 322 | 0.730 |
Why?
|
| Eye Diseases | 6 | 2009 | 669 | 0.680 |
Why?
|
| Pigment Epithelium of Eye | 8 | 2004 | 220 | 0.670 |
Why?
|
| Rats, Long-Evans | 15 | 2007 | 387 | 0.670 |
Why?
|
| Capillary Permeability | 12 | 2003 | 798 | 0.580 |
Why?
|
| Visual Acuity | 16 | 2022 | 2530 | 0.560 |
Why?
|
| Proto-Oncogene Proteins c-sis | 2 | 2015 | 251 | 0.560 |
Why?
|
| Hypoxia-Inducible Factor 1 | 2 | 2015 | 198 | 0.550 |
Why?
|
| Angiopoietin-2 | 2 | 2022 | 173 | 0.540 |
Why?
|
| Leukocytes | 11 | 2003 | 2043 | 0.540 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 5 | 2003 | 1676 | 0.530 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 4 | 2022 | 664 | 0.530 |
Why?
|
| Complement Pathway, Alternative | 1 | 2015 | 126 | 0.520 |
Why?
|
| Cell Adhesion | 13 | 2009 | 3144 | 0.510 |
Why?
|
| Ischemia | 7 | 2003 | 1907 | 0.510 |
Why?
|
| Iris | 7 | 1998 | 239 | 0.500 |
Why?
|
| Fluorescein-5-isothiocyanate | 4 | 2003 | 225 | 0.490 |
Why?
|
| Eye Injuries | 4 | 2006 | 245 | 0.460 |
Why?
|
| Fluorescein Angiography | 20 | 2014 | 940 | 0.440 |
Why?
|
| Drug Delivery Systems | 6 | 2021 | 2219 | 0.440 |
Why?
|
| Antibodies, Monoclonal | 12 | 2022 | 9274 | 0.430 |
Why?
|
| Sclera | 4 | 2003 | 200 | 0.430 |
Why?
|
| RNA, Messenger | 22 | 2008 | 13033 | 0.420 |
Why?
|
| Intravitreal Injections | 7 | 2024 | 344 | 0.410 |
Why?
|
| Injections | 14 | 2009 | 840 | 0.380 |
Why?
|
| Recombinant Fusion Proteins | 5 | 2022 | 3772 | 0.380 |
Why?
|
| Rats | 26 | 2007 | 24260 | 0.370 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 6 | 2008 | 552 | 0.360 |
Why?
|
| Edema | 3 | 2022 | 789 | 0.350 |
Why?
|
| Gene Expression | 9 | 2001 | 7799 | 0.350 |
Why?
|
| Oligonucleotides | 4 | 2005 | 572 | 0.320 |
Why?
|
| Animals | 82 | 2014 | 168757 | 0.320 |
Why?
|
| Retinal Vein Occlusion | 4 | 2011 | 137 | 0.300 |
Why?
|
| Glaucoma, Neovascular | 2 | 1998 | 36 | 0.300 |
Why?
|
| Keratitis | 3 | 2000 | 268 | 0.300 |
Why?
|
| Models, Econometric | 1 | 2007 | 218 | 0.290 |
Why?
|
| Complement System Proteins | 1 | 2010 | 795 | 0.280 |
Why?
|
| Retinal Diseases | 3 | 2003 | 683 | 0.260 |
Why?
|
| Evans Blue | 3 | 2001 | 45 | 0.260 |
Why?
|
| Fuchs' Endothelial Dystrophy | 2 | 2000 | 84 | 0.260 |
Why?
|
| Blotting, Northern | 9 | 2003 | 1581 | 0.260 |
Why?
|
| Ocular Physiological Phenomena | 1 | 2005 | 70 | 0.250 |
Why?
|
| Nitric Oxide Synthase | 3 | 2002 | 916 | 0.250 |
Why?
|
| Receptors, Leukocyte-Adhesion | 2 | 2002 | 53 | 0.240 |
Why?
|
| Immunoenzyme Techniques | 7 | 2007 | 1799 | 0.240 |
Why?
|
| Retinal Degeneration | 2 | 2006 | 415 | 0.240 |
Why?
|
| Fibroblast Growth Factor 2 | 7 | 2009 | 599 | 0.230 |
Why?
|
| Macaca fascicularis | 12 | 2009 | 915 | 0.230 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 9 | 2014 | 3870 | 0.230 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 3 | 2008 | 2282 | 0.230 |
Why?
|
| Insulin-Like Growth Factor I | 3 | 2004 | 2015 | 0.230 |
Why?
|
| Mice, Inbred C57BL | 23 | 2014 | 21827 | 0.230 |
Why?
|
| Aqueous Humor | 3 | 2000 | 161 | 0.230 |
Why?
|
| Infusion Pumps, Implantable | 2 | 2002 | 156 | 0.220 |
Why?
|
| Endothelium, Corneal | 3 | 2003 | 199 | 0.220 |
Why?
|
| Receptors, Immunologic | 2 | 2007 | 1423 | 0.220 |
Why?
|
| Neutrophils | 5 | 2003 | 3719 | 0.220 |
Why?
|
| Rabbits | 10 | 2009 | 4894 | 0.210 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2004 | 452 | 0.210 |
Why?
|
| Coloring Agents | 3 | 2001 | 566 | 0.210 |
Why?
|
| Retinitis | 1 | 2002 | 35 | 0.210 |
Why?
|
| Plasminogen | 1 | 2002 | 152 | 0.210 |
Why?
|
| Conjunctiva | 2 | 2003 | 494 | 0.210 |
Why?
|
| Drug Implants | 2 | 2019 | 244 | 0.210 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 2 | 2007 | 546 | 0.210 |
Why?
|
| Macula Lutea | 2 | 2022 | 151 | 0.200 |
Why?
|
| Sialoglycoproteins | 1 | 2002 | 318 | 0.200 |
Why?
|
| Polyglycolic Acid | 1 | 2003 | 407 | 0.200 |
Why?
|
| Membrane Glycoproteins | 5 | 2003 | 3768 | 0.200 |
Why?
|
| Capillary Leak Syndrome | 1 | 2001 | 31 | 0.200 |
Why?
|
| Dextrans | 2 | 2000 | 595 | 0.190 |
Why?
|
| Drug Therapy, Combination | 3 | 2009 | 6489 | 0.190 |
Why?
|
| Gene Expression Regulation | 4 | 2007 | 12072 | 0.190 |
Why?
|
| Conjunctivitis, Viral | 1 | 2000 | 6 | 0.190 |
Why?
|
| Eye Proteins | 2 | 2001 | 646 | 0.190 |
Why?
|
| Serum Albumin, Bovine | 2 | 2003 | 324 | 0.180 |
Why?
|
| Ketorolac | 1 | 2000 | 79 | 0.180 |
Why?
|
| Disease Models, Animal | 16 | 2014 | 18029 | 0.180 |
Why?
|
| Goblet Cells | 1 | 2003 | 287 | 0.180 |
Why?
|
| Ophthalmic Solutions | 2 | 2000 | 317 | 0.180 |
Why?
|
| Cyclic CMP | 1 | 1999 | 6 | 0.180 |
Why?
|
| Epithelium, Corneal | 1 | 2002 | 247 | 0.180 |
Why?
|
| Antibodies, Bispecific | 1 | 2022 | 164 | 0.180 |
Why?
|
| Integrin alpha5beta1 | 2 | 2009 | 38 | 0.180 |
Why?
|
| Retinal Vein | 2 | 2006 | 47 | 0.170 |
Why?
|
| Humans | 80 | 2024 | 744343 | 0.170 |
Why?
|
| Mice | 31 | 2014 | 81183 | 0.170 |
Why?
|
| Retinal Pigment Epithelium | 2 | 2014 | 302 | 0.170 |
Why?
|
| Transfection | 3 | 2002 | 5892 | 0.170 |
Why?
|
| Conjunctivitis, Inclusion | 1 | 1998 | 5 | 0.160 |
Why?
|
| Retinal Ganglion Cells | 4 | 2009 | 770 | 0.160 |
Why?
|
| Proto-Oncogene Proteins | 5 | 2004 | 4554 | 0.160 |
Why?
|
| Receptors, Growth Factor | 1 | 1999 | 334 | 0.160 |
Why?
|
| Trachoma | 1 | 1998 | 29 | 0.160 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 3 | 2002 | 1660 | 0.160 |
Why?
|
| Cattle | 8 | 2003 | 3922 | 0.160 |
Why?
|
| Dose-Response Relationship, Drug | 10 | 2009 | 10943 | 0.160 |
Why?
|
| Male | 50 | 2022 | 350118 | 0.150 |
Why?
|
| Corneal Dystrophies, Hereditary | 2 | 2001 | 81 | 0.150 |
Why?
|
| Immunoglobulin G | 4 | 2007 | 4560 | 0.150 |
Why?
|
| Lactic Acid | 1 | 2003 | 1133 | 0.150 |
Why?
|
| Fundus Oculi | 5 | 2019 | 473 | 0.150 |
Why?
|
| Blotting, Western | 5 | 2004 | 5179 | 0.140 |
Why?
|
| Acridine Orange | 3 | 2000 | 26 | 0.140 |
Why?
|
| Inflammation | 5 | 2010 | 10638 | 0.140 |
Why?
|
| Retinal Hemorrhage | 1 | 1996 | 96 | 0.140 |
Why?
|
| Delayed-Action Preparations | 2 | 2019 | 968 | 0.140 |
Why?
|
| Insulin | 2 | 2002 | 6580 | 0.140 |
Why?
|
| Plasmids | 1 | 2001 | 2307 | 0.140 |
Why?
|
| Angiogenesis Inducing Agents | 1 | 1998 | 282 | 0.140 |
Why?
|
| Photography | 1 | 2019 | 520 | 0.130 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 5 | 2004 | 4751 | 0.130 |
Why?
|
| Corneal Transplantation | 1 | 2000 | 386 | 0.130 |
Why?
|
| Hyperoxia | 1 | 1997 | 262 | 0.130 |
Why?
|
| Polymers | 1 | 2003 | 1621 | 0.130 |
Why?
|
| Cost-Benefit Analysis | 1 | 2007 | 5391 | 0.130 |
Why?
|
| Nitric Oxide Synthase Type III | 3 | 2002 | 689 | 0.130 |
Why?
|
| Mice, Transgenic | 6 | 2007 | 9734 | 0.120 |
Why?
|
| Biocompatible Materials | 2 | 2003 | 1736 | 0.120 |
Why?
|
| In Situ Hybridization | 5 | 1999 | 1950 | 0.120 |
Why?
|
| Protein Isoforms | 3 | 2004 | 1730 | 0.120 |
Why?
|
| Fas Ligand Protein | 3 | 2003 | 216 | 0.120 |
Why?
|
| Rats, Sprague-Dawley | 6 | 2001 | 8301 | 0.120 |
Why?
|
| Nitric Oxide | 2 | 2002 | 2132 | 0.120 |
Why?
|
| Tumor Necrosis Factor-alpha | 3 | 2002 | 4420 | 0.120 |
Why?
|
| Neoplasms | 2 | 2016 | 21683 | 0.120 |
Why?
|
| Culture Media, Conditioned | 3 | 2002 | 537 | 0.120 |
Why?
|
| Epidermolysis Bullosa Simplex | 1 | 1993 | 13 | 0.110 |
Why?
|
| NF-kappa B | 4 | 2004 | 2499 | 0.110 |
Why?
|
| Cell Division | 6 | 2003 | 4568 | 0.110 |
Why?
|
| Electrophoretic Mobility Shift Assay | 2 | 2004 | 300 | 0.110 |
Why?
|
| DNA | 4 | 2003 | 7301 | 0.110 |
Why?
|
| Cells, Cultured | 10 | 2003 | 19229 | 0.110 |
Why?
|
| Neuroprotective Agents | 3 | 2009 | 941 | 0.110 |
Why?
|
| Treatment Outcome | 12 | 2022 | 63114 | 0.110 |
Why?
|
| Blood Platelets | 1 | 2003 | 2508 | 0.110 |
Why?
|
| Double-Blind Method | 9 | 2022 | 12026 | 0.110 |
Why?
|
| Recombinant Proteins | 8 | 2007 | 6622 | 0.110 |
Why?
|
| Half-Life | 2 | 2007 | 661 | 0.100 |
Why?
|
| Tomography, Optical Coherence | 4 | 2019 | 2657 | 0.100 |
Why?
|
| Wounds, Nonpenetrating | 1 | 1998 | 794 | 0.100 |
Why?
|
| beta-Galactosidase | 2 | 2003 | 573 | 0.100 |
Why?
|
| Neovascularization, Physiologic | 4 | 2003 | 1351 | 0.090 |
Why?
|
| Proteomics | 1 | 2024 | 3638 | 0.090 |
Why?
|
| Reactive Oxygen Species | 2 | 2003 | 2077 | 0.090 |
Why?
|
| Time Factors | 8 | 2016 | 40075 | 0.090 |
Why?
|
| Complement Inactivating Agents | 1 | 2010 | 50 | 0.090 |
Why?
|
| Peptide Fragments | 1 | 2002 | 5097 | 0.090 |
Why?
|
| Retinal Drusen | 1 | 2010 | 66 | 0.090 |
Why?
|
| Intraocular Pressure | 4 | 2008 | 1270 | 0.090 |
Why?
|
| Cataract Extraction | 1 | 1994 | 481 | 0.090 |
Why?
|
| Models, Immunological | 2 | 2010 | 527 | 0.090 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 2 | 2004 | 627 | 0.090 |
Why?
|
| Geographic Atrophy | 1 | 2010 | 66 | 0.090 |
Why?
|
| beta-Alanine | 1 | 2009 | 74 | 0.090 |
Why?
|
| Eye Enucleation | 1 | 2009 | 128 | 0.080 |
Why?
|
| Propionates | 1 | 2009 | 169 | 0.080 |
Why?
|
| Vitreoretinopathy, Proliferative | 1 | 2009 | 68 | 0.080 |
Why?
|
| Permeability | 2 | 2002 | 738 | 0.080 |
Why?
|
| Stem Cells | 1 | 2002 | 3567 | 0.080 |
Why?
|
| Luminescent Proteins | 2 | 2002 | 853 | 0.080 |
Why?
|
| Antibodies, Blocking | 2 | 2000 | 253 | 0.080 |
Why?
|
| Leukocyte Count | 2 | 2004 | 1588 | 0.080 |
Why?
|
| Mice, Knockout | 7 | 2004 | 14557 | 0.080 |
Why?
|
| Complement Activation | 1 | 2010 | 453 | 0.080 |
Why?
|
| Optic Nerve Injuries | 1 | 2009 | 150 | 0.080 |
Why?
|
| Clinical Trials as Topic | 4 | 2008 | 7913 | 0.080 |
Why?
|
| Capillaries | 2 | 2003 | 773 | 0.080 |
Why?
|
| Immunohistochemistry | 7 | 2009 | 11366 | 0.080 |
Why?
|
| Epithelium | 3 | 2002 | 1679 | 0.080 |
Why?
|
| Pyrrolidines | 1 | 2009 | 342 | 0.080 |
Why?
|
| Sucralfate | 2 | 1996 | 12 | 0.070 |
Why?
|
| Ophthalmoscopy | 2 | 2014 | 176 | 0.070 |
Why?
|
| Artificial Intelligence | 1 | 2020 | 2214 | 0.070 |
Why?
|
| Mitogen-Activated Protein Kinases | 2 | 2002 | 1285 | 0.070 |
Why?
|
| Nuclear Proteins | 1 | 2002 | 5853 | 0.070 |
Why?
|
| Gene Deletion | 3 | 2003 | 2751 | 0.070 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 3 | 2007 | 428 | 0.070 |
Why?
|
| Concanavalin A | 2 | 2003 | 191 | 0.070 |
Why?
|
| Injections, Intraperitoneal | 1 | 2007 | 425 | 0.070 |
Why?
|
| Collagen Type IV | 1 | 2006 | 140 | 0.070 |
Why?
|
| Green Fluorescent Proteins | 2 | 2002 | 2088 | 0.070 |
Why?
|
| Corneal Diseases | 1 | 1993 | 636 | 0.070 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2019 | 3327 | 0.070 |
Why?
|
| Aminopyridines | 1 | 2009 | 542 | 0.070 |
Why?
|
| Aged | 17 | 2022 | 163280 | 0.070 |
Why?
|
| Phosphopyruvate Hydratase | 1 | 1985 | 135 | 0.070 |
Why?
|
| Microspheres | 3 | 2003 | 777 | 0.070 |
Why?
|
| Retinal Detachment | 1 | 2009 | 411 | 0.070 |
Why?
|
| Random Allocation | 2 | 2003 | 2429 | 0.060 |
Why?
|
| Female | 25 | 2022 | 380194 | 0.060 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 1996 | 3617 | 0.060 |
Why?
|
| Up-Regulation | 3 | 2003 | 4217 | 0.060 |
Why?
|
| Aged, 80 and over | 10 | 2021 | 57776 | 0.060 |
Why?
|
| Bromodeoxyuridine | 2 | 2002 | 322 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2004 | 2503 | 0.060 |
Why?
|
| DNA-Binding Proteins | 1 | 2002 | 9648 | 0.060 |
Why?
|
| Antibodies | 2 | 2006 | 2460 | 0.060 |
Why?
|
| Markov Chains | 1 | 2007 | 969 | 0.060 |
Why?
|
| RNA | 3 | 2000 | 2749 | 0.060 |
Why?
|
| MAP Kinase Kinase 4 | 1 | 2004 | 148 | 0.060 |
Why?
|
| Photochemotherapy | 2 | 2008 | 807 | 0.060 |
Why?
|
| Proteinuria | 1 | 2007 | 658 | 0.060 |
Why?
|
| Conjunctival Diseases | 2 | 1997 | 122 | 0.060 |
Why?
|
| Phosphatidylinositol 3-Kinases | 2 | 2004 | 2938 | 0.060 |
Why?
|
| Optic Nerve Diseases | 1 | 2007 | 327 | 0.060 |
Why?
|
| Diabetes Mellitus | 1 | 2002 | 5751 | 0.060 |
Why?
|
| Epithelial Cells | 3 | 2003 | 3690 | 0.060 |
Why?
|
| Galactose | 1 | 2004 | 306 | 0.060 |
Why?
|
| History, 21st Century | 1 | 2009 | 1534 | 0.060 |
Why?
|
| Ophthalmology | 1 | 2009 | 508 | 0.050 |
Why?
|
| Fluorophotometry | 1 | 2002 | 40 | 0.050 |
Why?
|
| Transcription Factor AP-1 | 1 | 2004 | 317 | 0.050 |
Why?
|
| Cell Migration Inhibition | 1 | 2002 | 96 | 0.050 |
Why?
|
| Angiostatins | 1 | 2002 | 67 | 0.050 |
Why?
|
| Middle Aged | 16 | 2022 | 213383 | 0.050 |
Why?
|
| Circular Dichroism | 1 | 2003 | 354 | 0.050 |
Why?
|
| Molecular Biology | 1 | 2006 | 596 | 0.050 |
Why?
|
| Erythropoietin | 1 | 2007 | 726 | 0.050 |
Why?
|
| Jurkat Cells | 1 | 2004 | 743 | 0.050 |
Why?
|
| Fibrosis | 1 | 2009 | 2029 | 0.050 |
Why?
|
| DNA Primers | 4 | 2001 | 2892 | 0.050 |
Why?
|
| Lasers | 1 | 2006 | 952 | 0.050 |
Why?
|
| Umbilical Veins | 1 | 2003 | 433 | 0.050 |
Why?
|
| Immunoglobulin M | 1 | 2007 | 1537 | 0.050 |
Why?
|
| Thiazines | 1 | 2002 | 38 | 0.050 |
Why?
|
| Immunoglobulin Fragments | 1 | 2002 | 84 | 0.050 |
Why?
|
| Carcinoma, Lewis Lung | 1 | 2002 | 114 | 0.050 |
Why?
|
| Angiopoietin-1 | 1 | 2002 | 114 | 0.050 |
Why?
|
| Kinetics | 2 | 2002 | 6473 | 0.050 |
Why?
|
| Receptors, Interleukin-2 | 1 | 2003 | 573 | 0.050 |
Why?
|
| Nitrites | 1 | 2002 | 160 | 0.050 |
Why?
|
| Antioxidants | 3 | 2003 | 1663 | 0.050 |
Why?
|
| NG-Nitroarginine Methyl Ester | 1 | 2002 | 255 | 0.050 |
Why?
|
| Animals, Newborn | 2 | 2006 | 2726 | 0.050 |
Why?
|
| Apoptosis | 5 | 2007 | 9727 | 0.050 |
Why?
|
| Liver Regeneration | 1 | 2003 | 210 | 0.050 |
Why?
|
| Receptors, Interleukin-1 | 1 | 2002 | 262 | 0.050 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2004 | 648 | 0.050 |
Why?
|
| Retinopathy of Prematurity | 1 | 2006 | 421 | 0.050 |
Why?
|
| Expressed Sequence Tags | 1 | 2001 | 255 | 0.050 |
Why?
|
| 14-3-3 Proteins | 1 | 2002 | 214 | 0.050 |
Why?
|
| Antigens, CD34 | 1 | 2003 | 657 | 0.050 |
Why?
|
| Administration, Topical | 2 | 2000 | 690 | 0.050 |
Why?
|
| History, 20th Century | 1 | 2009 | 2740 | 0.050 |
Why?
|
| Tyrosine 3-Monooxygenase | 1 | 2002 | 375 | 0.050 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 1 | 2002 | 297 | 0.050 |
Why?
|
| Promoter Regions, Genetic | 3 | 2004 | 5867 | 0.050 |
Why?
|
| Chemotaxis, Leukocyte | 1 | 2004 | 675 | 0.050 |
Why?
|
| Molecular Weight | 2 | 2000 | 2255 | 0.050 |
Why?
|
| Needles | 1 | 2024 | 449 | 0.050 |
Why?
|
| Cell Count | 2 | 2003 | 1856 | 0.050 |
Why?
|
| Interviews as Topic | 1 | 2007 | 2539 | 0.050 |
Why?
|
| Proliferating Cell Nuclear Antigen | 2 | 2003 | 285 | 0.050 |
Why?
|
| Diffusion Chambers, Culture | 1 | 2000 | 50 | 0.050 |
Why?
|
| Receptors, CCR5 | 1 | 2003 | 497 | 0.050 |
Why?
|
| Enzyme Inhibitors | 3 | 2003 | 3798 | 0.050 |
Why?
|
| Reperfusion Injury | 1 | 2007 | 1026 | 0.050 |
Why?
|
| Pinocytosis | 1 | 2000 | 65 | 0.050 |
Why?
|
| Electroretinography | 2 | 2014 | 509 | 0.050 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2002 | 534 | 0.050 |
Why?
|
| Gelsolin | 1 | 2001 | 190 | 0.050 |
Why?
|
| Receptors, Chemokine | 1 | 2003 | 669 | 0.040 |
Why?
|
| Cell Survival | 2 | 2007 | 5882 | 0.040 |
Why?
|
| Transport Vesicles | 1 | 2000 | 83 | 0.040 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2002 | 371 | 0.040 |
Why?
|
| Epitopes | 1 | 2006 | 2571 | 0.040 |
Why?
|
| Debridement | 1 | 2002 | 492 | 0.040 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 2002 | 707 | 0.040 |
Why?
|
| Hepatectomy | 1 | 2003 | 550 | 0.040 |
Why?
|
| Neutrophil Activation | 1 | 2000 | 186 | 0.040 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2002 | 595 | 0.040 |
Why?
|
| Macrophage-1 Antigen | 1 | 2000 | 290 | 0.040 |
Why?
|
| Diabetes Complications | 1 | 2006 | 1359 | 0.040 |
Why?
|
| Nitric Oxide Donors | 1 | 1999 | 121 | 0.040 |
Why?
|
| Nitroprusside | 1 | 1999 | 275 | 0.040 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2008 | 1855 | 0.040 |
Why?
|
| Cell Death | 2 | 2002 | 1706 | 0.040 |
Why?
|
| Aging | 1 | 1998 | 8664 | 0.040 |
Why?
|
| Proteoglycans | 1 | 2002 | 835 | 0.040 |
Why?
|
| Lymphocyte Function-Associated Antigen-1 | 1 | 2000 | 378 | 0.040 |
Why?
|
| Interleukin-1 | 1 | 2002 | 1263 | 0.040 |
Why?
|
| Neoplasm Transplantation | 1 | 2002 | 2085 | 0.040 |
Why?
|
| Drug Carriers | 1 | 2003 | 693 | 0.040 |
Why?
|
| Keratoconus | 1 | 2000 | 121 | 0.040 |
Why?
|
| Clinical Competence | 1 | 1994 | 4687 | 0.040 |
Why?
|
| Fluorescent Antibody Technique | 2 | 1993 | 2505 | 0.040 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 1999 | 821 | 0.040 |
Why?
|
| Tonometry, Ocular | 2 | 2009 | 237 | 0.040 |
Why?
|
| Spectrometry, Fluorescence | 1 | 2000 | 689 | 0.040 |
Why?
|
| Hydrogen Peroxide | 2 | 2003 | 731 | 0.040 |
Why?
|
| Pyridines | 1 | 2009 | 2825 | 0.040 |
Why?
|
| Cell Hypoxia | 2 | 1997 | 675 | 0.040 |
Why?
|
| 3T3 Cells | 1 | 1999 | 1101 | 0.040 |
Why?
|
| Integrins | 1 | 2002 | 846 | 0.040 |
Why?
|
| Ribonucleases | 1 | 1998 | 287 | 0.040 |
Why?
|
| Glaucoma | 1 | 2007 | 1159 | 0.040 |
Why?
|
| Telomerase | 1 | 2002 | 730 | 0.040 |
Why?
|
| Combined Modality Therapy | 1 | 2009 | 8642 | 0.040 |
Why?
|
| E-Selectin | 1 | 1999 | 579 | 0.040 |
Why?
|
| Blood Circulation | 1 | 1998 | 251 | 0.040 |
Why?
|
| Peroxidase | 1 | 2000 | 611 | 0.040 |
Why?
|
| P-Selectin | 1 | 1999 | 600 | 0.040 |
Why?
|
| Diagnostic Techniques, Ophthalmological | 1 | 2019 | 245 | 0.040 |
Why?
|
| Prospective Studies | 6 | 2011 | 53288 | 0.040 |
Why?
|
| Cycloheximide | 1 | 1996 | 347 | 0.030 |
Why?
|
| Dactinomycin | 1 | 1996 | 318 | 0.030 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2001 | 849 | 0.030 |
Why?
|
| False Positive Reactions | 1 | 2019 | 981 | 0.030 |
Why?
|
| Genes, ras | 1 | 1999 | 690 | 0.030 |
Why?
|
| Cell Culture Techniques | 1 | 2004 | 1678 | 0.030 |
Why?
|
| Cell Line, Transformed | 1 | 1997 | 898 | 0.030 |
Why?
|
| Melanosis | 1 | 1997 | 78 | 0.030 |
Why?
|
| Trabecular Meshwork | 1 | 1996 | 99 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2019 | 9959 | 0.030 |
Why?
|
| Enzyme Activation | 1 | 2002 | 3701 | 0.030 |
Why?
|
| Tissue Donors | 2 | 2009 | 2240 | 0.030 |
Why?
|
| Transcription, Genetic | 3 | 2001 | 7722 | 0.030 |
Why?
|
| Organ Size | 1 | 2001 | 2252 | 0.030 |
Why?
|
| Protein Kinases | 1 | 2003 | 1640 | 0.030 |
Why?
|
| Light Coagulation | 1 | 1995 | 72 | 0.030 |
Why?
|
| Durapatite | 1 | 1996 | 161 | 0.030 |
Why?
|
| Transcriptional Activation | 1 | 2002 | 1783 | 0.030 |
Why?
|
| Bacterial Vaccines | 1 | 1998 | 403 | 0.030 |
Why?
|
| Reperfusion | 1 | 1996 | 284 | 0.030 |
Why?
|
| Superoxides | 1 | 1996 | 387 | 0.030 |
Why?
|
| Lacrimal Apparatus Diseases | 1 | 1996 | 65 | 0.030 |
Why?
|
| Oxygen | 2 | 1997 | 4189 | 0.030 |
Why?
|
| Risk | 1 | 2007 | 9687 | 0.030 |
Why?
|
| Microscopy, Electron | 2 | 2014 | 2645 | 0.030 |
Why?
|
| Receptor, IGF Type 1 | 1 | 1997 | 390 | 0.030 |
Why?
|
| Fluoroimmunoassay | 1 | 1994 | 33 | 0.030 |
Why?
|
| Flow Cytometry | 2 | 2009 | 5974 | 0.030 |
Why?
|
| Pregnancy Proteins | 1 | 1996 | 229 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2007 | 10252 | 0.030 |
Why?
|
| Conjunctivitis | 1 | 1996 | 158 | 0.030 |
Why?
|
| Cryotherapy | 1 | 1995 | 155 | 0.030 |
Why?
|
| Thiazoles | 1 | 2002 | 1483 | 0.030 |
Why?
|
| Laser Coagulation | 3 | 2003 | 326 | 0.030 |
Why?
|
| Metalloendopeptidases | 1 | 1996 | 396 | 0.030 |
Why?
|
| Factor VIII | 1 | 1996 | 347 | 0.030 |
Why?
|
| Polyethylenes | 1 | 1996 | 285 | 0.030 |
Why?
|
| Chlamydia Infections | 1 | 1998 | 365 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2024 | 5078 | 0.030 |
Why?
|
| Antisense Elements (Genetics) | 1 | 1993 | 37 | 0.030 |
Why?
|
| Monocytes | 1 | 2003 | 2596 | 0.030 |
Why?
|
| Eyelid Diseases | 1 | 1996 | 155 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2022 | 4933 | 0.030 |
Why?
|
| Microscopy, Confocal | 2 | 2014 | 1970 | 0.030 |
Why?
|
| RNA Probes | 1 | 1993 | 113 | 0.030 |
Why?
|
| Transcription Factors | 2 | 2004 | 12208 | 0.030 |
Why?
|
| Visual Pathways | 1 | 1998 | 565 | 0.030 |
Why?
|
| Keratoplasty, Penetrating | 1 | 1994 | 155 | 0.030 |
Why?
|
| Comorbidity | 1 | 2007 | 10388 | 0.030 |
Why?
|
| Descemet Membrane | 1 | 1993 | 73 | 0.030 |
Why?
|
| Macaca mulatta | 1 | 1999 | 2375 | 0.030 |
Why?
|
| Transforming Growth Factor beta | 1 | 2001 | 2007 | 0.030 |
Why?
|
| Cell Nucleus | 1 | 2002 | 2969 | 0.030 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2001 | 3920 | 0.030 |
Why?
|
| Calculi | 1 | 1992 | 46 | 0.030 |
Why?
|
| Hemodynamics | 1 | 2003 | 4199 | 0.030 |
Why?
|
| Interleukin-6 | 1 | 2002 | 3200 | 0.030 |
Why?
|
| Phosphorylation | 1 | 2004 | 8436 | 0.030 |
Why?
|
| Adult | 10 | 2013 | 214055 | 0.030 |
Why?
|
| Blood Glucose | 1 | 2007 | 6256 | 0.030 |
Why?
|
| Corneal Stroma | 1 | 1993 | 174 | 0.030 |
Why?
|
| Basement Membrane | 1 | 1993 | 356 | 0.030 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 1996 | 794 | 0.030 |
Why?
|
| Protease Inhibitors | 1 | 1996 | 791 | 0.030 |
Why?
|
| Cell Movement | 2 | 2009 | 5217 | 0.030 |
Why?
|
| Biopsy | 1 | 2024 | 6756 | 0.030 |
Why?
|
| Cataract | 1 | 1998 | 834 | 0.030 |
Why?
|
| Endothelium | 2 | 2003 | 778 | 0.030 |
Why?
|
| Blood Pressure | 1 | 2007 | 8554 | 0.020 |
Why?
|
| Collagen | 1 | 2000 | 2689 | 0.020 |
Why?
|
| Endothelial Cells | 1 | 2004 | 3479 | 0.020 |
Why?
|
| Mutation, Missense | 1 | 2001 | 2564 | 0.020 |
Why?
|
| Blood Flow Velocity | 2 | 2007 | 1423 | 0.020 |
Why?
|
| Glaucoma, Open-Angle | 1 | 1998 | 706 | 0.020 |
Why?
|
| Oxygen Consumption | 1 | 1997 | 1869 | 0.020 |
Why?
|
| HIV Envelope Protein gp120 | 1 | 1996 | 952 | 0.020 |
Why?
|
| Mice, Mutant Strains | 1 | 2014 | 1866 | 0.020 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 1993 | 1801 | 0.020 |
Why?
|
| Cell Line | 2 | 2009 | 15997 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2024 | 8324 | 0.020 |
Why?
|
| Sickness Impact Profile | 1 | 2011 | 302 | 0.020 |
Why?
|
| Aspirin | 1 | 2002 | 3282 | 0.020 |
Why?
|
| Glucose | 1 | 2002 | 4397 | 0.020 |
Why?
|
| California | 1 | 1994 | 1402 | 0.020 |
Why?
|
| Disease Progression | 1 | 2006 | 13284 | 0.020 |
Why?
|
| Virus Diseases | 1 | 1996 | 711 | 0.020 |
Why?
|
| Orbital Neoplasms | 1 | 1992 | 225 | 0.020 |
Why?
|
| Signal Transduction | 3 | 2014 | 23403 | 0.020 |
Why?
|
| Thrombosis | 1 | 2003 | 2968 | 0.020 |
Why?
|
| Epiretinal Membrane | 1 | 2009 | 68 | 0.020 |
Why?
|
| Insulin Resistance | 1 | 2003 | 3864 | 0.020 |
Why?
|
| Prostheses and Implants | 1 | 1996 | 1387 | 0.020 |
Why?
|
| Tissue Survival | 1 | 2009 | 118 | 0.020 |
Why?
|
| Safety | 2 | 2005 | 1186 | 0.020 |
Why?
|
| Interferon Type I | 1 | 1992 | 542 | 0.020 |
Why?
|
| Sequence Homology, Nucleic Acid | 2 | 2003 | 1085 | 0.020 |
Why?
|
| Infant, Newborn | 3 | 2024 | 25625 | 0.020 |
Why?
|
| Microcirculation | 2 | 2003 | 1286 | 0.020 |
Why?
|
| Neoplasm Proteins | 1 | 2001 | 3703 | 0.020 |
Why?
|
| Bacterial Infections | 1 | 1996 | 1401 | 0.020 |
Why?
|
| Receptors, Erythropoietin | 1 | 2007 | 147 | 0.020 |
Why?
|
| Intraoperative Complications | 1 | 1994 | 1198 | 0.020 |
Why?
|
| Protein Denaturation | 1 | 2006 | 237 | 0.020 |
Why?
|
| Hemangioma | 1 | 1992 | 738 | 0.020 |
Why?
|
| Memantine | 1 | 2007 | 100 | 0.020 |
Why?
|
| Alternative Splicing | 3 | 1996 | 1117 | 0.020 |
Why?
|
| Thromboplastin | 1 | 2008 | 291 | 0.020 |
Why?
|
| Immunochemistry | 1 | 1985 | 124 | 0.020 |
Why?
|
| Mice, Inbred DBA | 1 | 2007 | 642 | 0.020 |
Why?
|
| Fibronectins | 1 | 2009 | 726 | 0.020 |
Why?
|
| Porphyrins | 1 | 2008 | 348 | 0.020 |
Why?
|
| T-Lymphocytes | 1 | 2003 | 10180 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2001 | 9438 | 0.020 |
Why?
|
| Models, Biological | 1 | 2002 | 9583 | 0.020 |
Why?
|
| Membrane Proteins | 1 | 2002 | 7880 | 0.020 |
Why?
|
| Blotting, Southern | 2 | 1996 | 803 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2007 | 40561 | 0.020 |
Why?
|
| Organ Culture Techniques | 1 | 2007 | 813 | 0.020 |
Why?
|
| Postoperative Complications | 2 | 2000 | 15295 | 0.020 |
Why?
|
| Indocyanine Green | 1 | 2006 | 239 | 0.020 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2006 | 472 | 0.020 |
Why?
|
| Retrospective Studies | 2 | 2019 | 77449 | 0.010 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2008 | 1572 | 0.010 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2009 | 1375 | 0.010 |
Why?
|
| Interferon-alpha | 2 | 2002 | 895 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 3 | 2001 | 6171 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2019 | 14722 | 0.010 |
Why?
|
| Photosensitizing Agents | 1 | 2008 | 602 | 0.010 |
Why?
|
| Connective Tissue | 1 | 1985 | 420 | 0.010 |
Why?
|
| Optic Nerve | 1 | 2007 | 554 | 0.010 |
Why?
|
| Pericytes | 1 | 2006 | 292 | 0.010 |
Why?
|
| Sodium Hydroxide | 1 | 2003 | 44 | 0.010 |
Why?
|
| Thioctic Acid | 1 | 2003 | 23 | 0.010 |
Why?
|
| Receptors, Mitogen | 1 | 2003 | 62 | 0.010 |
Why?
|
| Rats, Zucker | 1 | 2003 | 128 | 0.010 |
Why?
|
| Base Sequence | 3 | 2003 | 12797 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2019 | 15076 | 0.010 |
Why?
|
| Fluorescein | 1 | 2003 | 171 | 0.010 |
Why?
|
| Maleimides | 1 | 2003 | 112 | 0.010 |
Why?
|
| Cyclohexanes | 1 | 2003 | 152 | 0.010 |
Why?
|
| Proteins | 1 | 1998 | 6103 | 0.010 |
Why?
|
| alpha-Tocopherol | 1 | 2003 | 127 | 0.010 |
Why?
|
| Oxidants | 1 | 2003 | 164 | 0.010 |
Why?
|
| Syndecans | 1 | 2002 | 79 | 0.010 |
Why?
|
| Receptors, CCR2 | 1 | 2003 | 212 | 0.010 |
Why?
|
| Staining and Labeling | 1 | 2006 | 1100 | 0.010 |
Why?
|
| Sesquiterpenes | 1 | 2003 | 177 | 0.010 |
Why?
|
| Eye Burns | 1 | 2003 | 103 | 0.010 |
Why?
|
| Activities of Daily Living | 1 | 2011 | 2418 | 0.010 |
Why?
|
| Prevalence | 1 | 1998 | 15226 | 0.010 |
Why?
|
| Uveitis, Anterior | 1 | 2002 | 101 | 0.010 |
Why?
|
| Burns, Chemical | 1 | 2003 | 159 | 0.010 |
Why?
|
| Molecular Sequence Data | 3 | 2003 | 18111 | 0.010 |
Why?
|
| Syndecan-1 | 1 | 2002 | 165 | 0.010 |
Why?
|
| Glioblastoma | 1 | 1996 | 3481 | 0.010 |
Why?
|
| Drug Combinations | 2 | 1996 | 1959 | 0.010 |
Why?
|
| Galectin 3 | 1 | 2003 | 227 | 0.010 |
Why?
|
| Protein Biosynthesis | 2 | 2001 | 2126 | 0.010 |
Why?
|
| Massachusetts | 1 | 1994 | 8663 | 0.010 |
Why?
|
| Hot Temperature | 1 | 2006 | 1354 | 0.010 |
Why?
|
| Microscopy, Immunoelectron | 1 | 2000 | 319 | 0.010 |
Why?
|
| Incidence | 1 | 1998 | 20947 | 0.010 |
Why?
|
| Gene Targeting | 1 | 2003 | 880 | 0.010 |
Why?
|
| Cryosurgery | 2 | 1997 | 453 | 0.010 |
Why?
|
| Microscopy, Fluorescence | 1 | 2007 | 2699 | 0.010 |
Why?
|
| Anti-Bacterial Agents | 1 | 1998 | 7181 | 0.010 |
Why?
|
| Apyrase | 1 | 2002 | 364 | 0.010 |
Why?
|
| Radiation Injuries | 1 | 2006 | 1180 | 0.010 |
Why?
|
| Extracellular Matrix | 1 | 2006 | 1741 | 0.010 |
Why?
|
| Coculture Techniques | 1 | 2002 | 1341 | 0.010 |
Why?
|
| Axons | 1 | 2007 | 1684 | 0.010 |
Why?
|
| Protein Kinase C | 1 | 2003 | 1227 | 0.010 |
Why?
|
| Melanoma | 1 | 1996 | 5510 | 0.010 |
Why?
|
| Lung Neoplasms | 1 | 2002 | 13102 | 0.010 |
Why?
|
| Thalidomide | 1 | 2002 | 890 | 0.010 |
Why?
|
| Transgenes | 1 | 2001 | 1009 | 0.010 |
Why?
|
| Injections, Intravenous | 1 | 2000 | 1420 | 0.010 |
Why?
|
| Polyhydroxyethyl Methacrylate | 1 | 1996 | 31 | 0.010 |
Why?
|
| Phenotype | 1 | 2014 | 16365 | 0.010 |
Why?
|
| Electrophoresis, Agar Gel | 1 | 1996 | 212 | 0.010 |
Why?
|
| Hepatocytes | 1 | 2003 | 1211 | 0.010 |
Why?
|
| Risk Factors | 1 | 2003 | 72290 | 0.010 |
Why?
|
| Eye Infections, Parasitic | 1 | 1996 | 24 | 0.010 |
Why?
|
| Porosity | 1 | 1996 | 362 | 0.010 |
Why?
|
| Insulin-Like Growth Factor II | 1 | 1997 | 271 | 0.010 |
Why?
|
| Indoles | 1 | 2003 | 1839 | 0.010 |
Why?
|
| Amino Acid Sequence | 2 | 1996 | 13815 | 0.010 |
Why?
|
| Bone Marrow Transplantation | 1 | 2002 | 2765 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2009 | 10481 | 0.010 |
Why?
|
| Radiography | 1 | 2004 | 7023 | 0.010 |
Why?
|
| Orbit | 1 | 1996 | 426 | 0.010 |
Why?
|
| Mice, Inbred Strains | 1 | 1996 | 1827 | 0.010 |
Why?
|
| Introns | 1 | 1996 | 991 | 0.010 |
Why?
|
| Mice, Inbred BALB C | 1 | 2002 | 6386 | 0.010 |
Why?
|
| Pedigree | 1 | 2001 | 4644 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 1996 | 2050 | 0.010 |
Why?
|
| Brain | 1 | 1999 | 26385 | 0.010 |
Why?
|
| Sclerosing Solutions | 1 | 1992 | 78 | 0.010 |
Why?
|
| Oxidative Stress | 1 | 2003 | 3086 | 0.010 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 1996 | 2839 | 0.010 |
Why?
|
| Hydrogels | 1 | 1996 | 724 | 0.010 |
Why?
|
| United States | 1 | 1998 | 69872 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 1996 | 4320 | 0.010 |
Why?
|
| Exons | 1 | 1996 | 2437 | 0.010 |
Why?
|
| Laser Therapy | 1 | 1997 | 1072 | 0.010 |
Why?
|
| Child | 1 | 1998 | 77709 | 0.010 |
Why?
|
| Adolescent | 1 | 1998 | 85781 | 0.010 |
Why?
|
| Terminology as Topic | 1 | 1997 | 1547 | 0.010 |
Why?
|
| Liver | 1 | 2003 | 7474 | 0.000 |
Why?
|
| Acute Disease | 1 | 1996 | 7149 | 0.000 |
Why?
|
| Age Factors | 1 | 2001 | 18370 | 0.000 |
Why?
|
| Glucocorticoids | 1 | 1992 | 2107 | 0.000 |
Why?
|
| Diagnosis, Differential | 1 | 1997 | 12959 | 0.000 |
Why?
|
| Chronic Disease | 1 | 1996 | 9146 | 0.000 |
Why?
|
| Genetic Variation | 1 | 1996 | 6544 | 0.000 |
Why?
|
| Prognosis | 1 | 1997 | 29063 | 0.000 |
Why?
|
| Antineoplastic Agents | 1 | 1997 | 13695 | 0.000 |
Why?
|
| Infant | 1 | 1992 | 35136 | 0.000 |
Why?
|